Oyster Point Pharma, Inc v. Lupin Ltd

Court

District Court, D. New Jersey (D.N.J.)
Official Court Website →

Assigned judge

Michael E. Farbiarz · 228 cases in index

Docket number

2:25-cv-17843

Cause

35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

11/21/2025

623 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Oyster Point Pharma, Inc · 6 cases
• defendant · Lupin Ltd · 127 cases

Part of a Larger Litigation Pattern

This is one of 128 Patent - ANDA cases in our index naming Lupin Ltd — a possible mass-tort or coordinated-litigation cluster.

• Takeda Pharmaceuticals U.S.A., Inc v. Lupin, Ltd
  District Court, D. New JerseyFiled 07/01/2025
• Jazz Pharmaceuticals Ireland Limited v. Lupin Ltd
  District Court, D. New JerseyFiled 08/27/2024
• Amicus Therapeutics US, LLC v. Lupin Ltd
  District Court, D. DelawareFiled 09/01/2023
• Astellas Pharma Inc v. Lupin Ltd
  District Court, D. DelawareFiled 07/28/2023
• Novo Nordisk Inc v. Lupin Ltd
  District Court, D. New JerseyFiled 07/27/2023
• Novo Nordisk Inc v. Lupin Ltd
  District Court, D. New JerseyFiled 07/27/2023

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Oyster Point Pharma, Inc v. Lupin Ltd?

Oyster Point Pharma, Inc v. Lupin Ltd is a federal patent - anda lawsuit filed on 11/21/2025 in the District Court, D. New Jersey. The case is currently open in the federal court system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. New Jersey, docket number 2:25-cv-17843.

When was the case filed?

Oyster Point Pharma, Inc v. Lupin Ltd was filed on 11/21/2025. The case is currently open.

What law is the case brought under?

The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.